Ursolisin

Ursodeoxycholic acid

Ursolisin

Active substance

Ursodeoxycholic acid

Strenght and pharmaceutical forms

150 mg hard capsules – 20 hard capsules
150 mg hard capsules – 30 hard capsules
150 mg hard capsules – 40 hard capsules
300 mg hard capsules – 10 hard capsules
300 mg hard capsules – 20 hard capsules

ATC

A05AA02; Hepatobiliary antilithogen, litolithic

Therapeutic Indications

Qualitative and quantitative alterations of biligenetic function, including bile-overexpressing cholesterol forms, to oppose the formation of cholesterol calculations or to achieve conditions for dissolution if radiolucent calculations already exist: in particular, gallbladder stones in functional gallbladder and calculations in residual choledocus or recurrent ones after surgery on the bile ducts; Biliary dyspepsia.

null

Download area

Summary of Product Characteristics - Ursolisin

Clinical Review from British Journal of Medicine & Medical Research


Products of the same therapeutic areas

Events

13-14/09/2019

SCLEROTHERAPY & VENOUS ABLATION

Pisa Palazzo dei Congressi

Primo congresso intersocietario Associazione Flebologica Italiana, Società Italiana FleboLinfologica, Società Italiana di Flebologia Clinica e Sperimentale

 Download

14-16/06/2019

33° Congresso Nazionale della Società Italiana per lo Studio delle Cefalee

Napoli

Congresso Nazionale della Società Italiana per lo Studio delle Cefalee